Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevasemten (EDG-5506) in adults with Becker muscular dystrophy (ARCH)
NCT05160415Phase 1Completed
- Start
- Dec 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sevasemten in Becker muscular dystrophy (BMD). Primary endpoints: Percentage of Participants Treated With Sevasemten Experiencing AEs at 25 months, Frequency of AEs in Those Treated With Sevasemten at 25 months and 1 more. Started Dec 2021; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT05160415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160415.